Nearly 100% Upside Potential Amid Biotech Innovation
Verastem, Inc. (NASDAQ: VSTM), a pioneering biopharmaceutical company, presents a compelling case for investors seeking exposure to the biotechnology sector, particularly in the promising field of cancer treatment. With a market capitalization of $480.67 million, this Massachusetts-based company is at the forefront of developing innovative therapies aimed at combating various forms of cancer.
Verastem’s current stock price stands at $7.81, marking a slight decrease of 0.01% recently. However, this minor dip belies the broader potential the stock holds. Analysts have set an ambitious average target price of $15.50, suggesting an impressive upside potential of 98.46%. The price range forecasted by analysts spans from $13.00 to…
